Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
- Founded
- 2019
- Status
- Active
- Stage
- Early
- Team size
- 15
- Location
- New York City, NY, USA; New York
- Category
- Biotech & Drug Discovery
- Sector
- Drug Discovery and Delivery
About Gilgamesh Pharmaceuticals
Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.
Clinical trials
2 registered trials with this company as lead sponsor, 2024.
- Phases
- Phase 2 (2)
- Status
- Completed (1), Recruiting (1)
- Conditions
- Major Depressive Disorder
Source: ClinicalTrials.gov.
Federal research funding
2 NIH awards totalling $3,588,425, FY2024 to FY2025.
- Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder
Source: NIH RePORTER.
Securities filings
7 Form D filings on record, 2020 to 2022.
Filed as Gilgamesh Pharmaceuticals, Inc.
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
